中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

9 records (took 0.024 seconds)

    COMPOSITIONS CONTAINING GROWTH FACTORS AND ANTIPLASTIC AGENTS
    1.
    发明申请
    COMPOSITIONS CONTAINING GROWTH FACTORS AND ANTIPLASTIC AGENTS 审中-公开
    含有生长因子和抗菌剂的组合物

    公开(公告)号：WO1995009004A1

    公开(公告)日：1995-04-06

    申请号：PCT/US1994011091

    申请日：1994-09-29

    Applicant: ALCON LABORATORIES, INC.

    Inventor： ALCON LABORATORIES, INC. ,  YORK, Billie, M. ,  NIXON, Jon, C. ,  SAMS, Karen, C.

    IPC: A61K38/18

    CPC classification number: A61K38/1808 ,  A61K31/404 ,  A61K38/1825 ,  A61K38/1841 ,  A61K38/1858 ,  A61K39/00 ,  C07K14/415 ,  C07K2319/00 ,  Y10S514/912 ,  Y10S514/913 ,  A61K2300/00

    Abstract: The intraocular use of combinations of lens epithelial cell growth stimulators (e.g., TGF- beta ) and antimetabolites (e.g., mitomycin C) is described. The combination is applied to the capsular bag to prevent or retard the formation of secondary cataracts following cataract surgery. The lens epithelial cell stimulators activate DNA synthesis in dormant lens epithelial cells, and thereby make those cells susceptible to the antimetabolites. This enables the antimetabolites to suppress the proliferation of lens epithelial cells to a much greater extent, relative to the proliferation observed when the metabolites alone are utilized. The increased suppression of the growth of lens epithelial cells results in a significant improvement in the ability to prevent or retard the formation of opacities on the lens capsule (i.e., secondary cataracts).

    Abstract translation: 描述了晶状体上皮细胞生长刺激剂（例如TGF-β）和抗代谢物（例如丝裂霉素C）的组合的眼内使用。 该组合应用于囊袋以防止或延缓白内障手术后继发性白内障的形成。 晶状体上皮细胞刺激剂激活休眠晶状体上皮细胞中的DNA合成，从而使这些细胞对抗代谢物敏感。 相对于单独使用代谢物时观察到的增殖，这使得抗代谢物能够在更大程度上抑制晶状体上皮细胞的增殖。 晶状体上皮细胞生长增加的抑制导致防止或延缓晶状体胶囊（即二次性白内障）不透明形成的能力的显着改善。

    USE OF TGF-'beta'3 TO REDUCE THE FORMATION OF SCAR TISSUE IN RESPONSE TO CORNEAL TRAUMA
    2.
    发明申请
    USE OF TGF-'beta'3 TO REDUCE THE FORMATION OF SCAR TISSUE IN RESPONSE TO CORNEAL TRAUMA 审中-公开
    TGF-β3用于减少脊髓组织在脊髓损伤中的形成

    公开(公告)号：WO1996032131A1

    公开(公告)日：1996-10-17

    申请号：PCT/US1995004572

    申请日：1995-04-14

    Applicant: ALCON LABORATORIES, INC.

    Inventor： ALCON LABORATORIES, INC. ,  NIXON, Jon, C. ,  YORK, Billie, M.

    IPC: A61K38/18

    CPC classification number: A61K38/1841

    Abstract: The use of TGF- beta 3 to reduce the formation of scar tissue as a result of trauma to the cornea of the eye is described. The invention is particularly directed to the use of TGF- beta 3 to reduce the formation of scar tissue in connection with ophthalmic surgical procedures involving the cornea, such as laser irradiation of the cornea. A composition containing TGF- beta 3 is applied to the site of the trauma to alter the production and composition of extracellular matrix synthesized by fibroblasts, and thereby reduce the formation of scar tissue and consequent impairment of vision.

    Abstract translation: 描述了使用TGF-β3来减少由眼睛角膜创伤引起的瘢痕组织的形成。 本发明特别涉及使用TGF-β3来减少与涉及角膜的眼科手术相关的瘢痕组织的形成，例如角膜的激光照射。 将包含TGF-β3的组合物应用于创伤部位，以改变由成纤维细胞合成的细胞外基质的生成和组成，从而减少瘢痕组织的形成，从而减少视力。

    COMPOSITIONS CONTAINING GROWTH FACTORS AND ANTIMETABOLITES
    4.
    发明申请
    COMPOSITIONS CONTAINING GROWTH FACTORS AND ANTIMETABOLITES 审中-公开
    含有生长因子和抗微生物剂的组合物

    公开(公告)号：WO1995009003A1

    公开(公告)日：1995-04-06

    申请号：PCT/US1994011087

    申请日：1994-09-29

    Applicant: ALCON LABORATORIES, INC.

    Inventor： ALCON LABORATORIES, INC. ,  YORK, Billie, M. ,  NIXON, Jon, C.

    IPC: A61K38/18

    CPC classification number: A61K33/24 ,  A61K38/1841 ,  Y10S514/913 ,  A61K38/08 ,  A61K31/70 ,  A61K31/505 ,  A61K31/40 ,  A61K31/355 ,  A61K2300/00

    Abstract: The intraocular use of combinations of stromal cell growth stimulators (e.g., TGF- beta ) and antimetabolites (e.g., mitomycin C) in connection with glaucoma filtration surgery is described. The combination is applied to the surgical site to attract, mitogenically activate, and neutralize the potential for extracellular matrix synthesis leading to scar formation by stromal cells. Without such treatment, the formation of scar tissue may lead to impairment of the outflow of aqueous humor at the surgical site, particularly the fistula. The mitogenic activation of the stromal cells makes these cells susceptible to the antimetabolites. This enables the antimetabolites to suppress the proliferation of the fibroblasts and other associated stromal cells to a much greater extent, relative to the proliferation seen when the metabolites alone are utilized. The increased suppression of the proliferation and metabolism of these cells results in a significant improvement in the ability to prevent or retard the formation of scar tissue, and thereby reduces the incidence of fistula closure following glaucoma filtration surgery.

    Abstract translation: 描述了与青光眼过滤手术相关的基质细胞生长刺激剂（例如TGF-β）和抗代谢物（例如丝裂霉素C）的组合的眼内使用。 该组合应用于手术部位以吸引，有丝分裂活化并中和细胞外基质合成的潜力，导致基质细胞形成瘢痕。 没有这种治疗，瘢痕组织的形成可能导致手术部位，特别是瘘管的房水流出的损害。 基质细胞的有丝分裂活化使得这些细胞对抗代谢物敏感。 这使得抗代谢物相对于单独使用代谢物时所见的增殖，可以大大地抑制成纤维细胞和其它相关基质细胞的增殖。 对这些细胞的增殖和代谢的增加的抑制导致防止或延缓瘢痕组织形成的能力的显着改善，从而降低青光眼过滤手术后瘘闭合的发生率。

    COMPOSITIONS CONTAINING GROWTH FACTORS AND ANTIMETABOLITES
    7.
    发明公开
    COMPOSITIONS CONTAINING GROWTH FACTORS AND ANTIMETABOLITES 失效
    WHICH生长因子和抗肿瘤基金组合物包。

    公开(公告)号：EP0670732A1

    公开(公告)日：1995-09-13

    申请号：EP94929388.0

    申请日：1994-09-29

    Applicant: ALCON LABORATORIES, INC.

    Inventor： YORK, Billie, M. ,  NIXON, Jon, C.

    IPC: A61K38 ,  A61K31 ,  A61K33 ,  A61P27

    CPC classification number: A61K33/24 ,  A61K38/1841 ,  Y10S514/913 ,  A61K38/08 ,  A61K31/70 ,  A61K31/505 ,  A61K31/40 ,  A61K31/355 ,  A61K2300/00

    Abstract: The intraocular use of combinations of stromal cell growth stimulators (e.g., TGF-β) and antimetabolites (e.g., mitomycin C) in connection with glaucoma filtration surgery is described. The combination is applied to the surgical site to attract, mitogenically activate, and neutralize the potential for extracellular matrix synthesis leading to scar formation by stromal cells. Without such treatment, the formation of scar tissue may lead to impairment of the outflow of aqueous humor at the surgical site, particularly the fistula. The mitogenic activation of the stromal cells makes these cells susceptible to the antimetabolites. This enables the antimetabolites to suppress the proliferation of the fibroblasts and other associated stromal cells to a much greater extent, relative to the proliferation seen when the metabolites alone are utilized. The increased suppression of the proliferation and metabolism of these cells results in a significant improvement in the ability to prevent or retard the formation of scar tissue, and thereby reduces the incidence of fistula closure following glaucoma filtration surgery.

Patent Agency Ranking